DCTH
DELCATH SYSTEMS, INC.
NASDAQ · Healthcare · Medical - Devices · US
$14.37
+2.06%Oct 19, 2026, 20:01 UTC
Delcath Systems announced that presentations on its clinical development programs will take place at the ESMO Congress 2026, scheduled for October 23–27 in Madrid.
Source:Aug 6, 2026, 14:51 UTC
Delcath Systems, Inc. reported Q2 2026 earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share.
Jul 9, 2026, 12:00 UTC
Delcath Systems dosed the first patient in a Phase 2 clinical trial of HEPZATO for liver-dominant metastatic breast cancer at the European Institute of Oncology in Milan, Italy.
Source: